IonTX

IonTX is a preclinical-stage biotechnology company spun out from the University of Texas Medical Branch (UTMB) that is developing a novel class of precision neurotherapeutics for neurological and neuropsychiatric disorders. The company's proprietary platform targets channel-associated proteins (ChAPs) to modulate protein-protein interactions (PPIs) that regulate voltage-gated sodium (Nav) channels, thereby normalizing the neuronal hypo- or hyperexcitability that drives disease pathology. IonTX's pipeline includes several first-in-class, non-opioid small molecules and peptidomimetics targeting peripheral pain (such as burn pain and diabetic neuropathy), anhedonia, cocaine use disorder, and early-stage Alzheimer's disease. By focusing on highly specific intracellular regulatory interfaces rather than traditional pore-blocking mechanisms, IonTX aims to deliver disease-modifying therapies with localized effects and minimized side effects.